The global clinical trials activity saw a decrease of 1.8% in Q4 2022, when compared with the rolling average of the last four quarters (Q4 2021 to Q3 2022), according to GlobalData.
Of the overall activity, industry sponsored trials accounted for a 54.4% share in Q4 2022, marking an increase of 4.5% in the total share when compared with the four-quarter average.
Go deeper with GlobalData
Non-industry sponsored trials accounted for a 45.6% share of all the clinical trials globally in Q4 2022, marking a decrease of 4.5% in the overall share when compared with the four-quarter average.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top therapy areas for industry and non-industry sponsored clinical trials in Q4 2022
Oncology was the leading therapy area for industry sponsored clinical trials in Q4 2022, accounting for a 30.2% share of all trials.
This was followed by the following therapy areas: Central Nervous System with a 15.9% share, Infectious Disease with a 12.7% share, Metabolic Disorders with a 7.3% share and Gastrointestinal with a 6.5% share.
In the last four quarters, Oncology held a lead over other therapy areas for industry sponsored clinical trials with a 27.3% share, followed by Infectious Disease with a 14.8% share, Central Nervous System with a 14.3% share, Metabolic Disorders with an 8.4% share, and Cardiovascular with an 8.0% share.
| Industry sponsored trials activity: 4-Quarter Avg. vs Q4 2022 | |||
|---|---|---|---|
| Therapy Area | 4-Quarter Avg. | Q4 2022 | Activity |
| Oncology | 27.3% | 30.2% |  |
| Central Nervous System | 14.3% | 15.9% | |
| Infectious Disease | 14.8% | 12.7% |  |
| Metabolic Disorders | 8.4% | 7.3% | |
| Gastrointestinal | 7.2% | 6.5% | |
| Cardiovascular | 8.0% | 6.4% | |
| Immunology | 5.4% | 5.5% | |
| Respiratory | 5.8% | 4.7% | |
| Dermatology | 5.3% | 4.3% | |
| Musculoskeletal Disorders | 4.0% | 3.3% | |
| Ophthalmology | 2.9% | 3.3% | |
| Hematological Disorders | 3.0% | 2.9% | |
| Genito Urinary System And Sex Hormones | 2.7% | 2.6% | |
| Genetic Disorders | 1.8% | 2.2% | |
| Women’s Health | 2.0% | 1.7% | |
| Male Health | 0.9% | 0.8% | |
| Ear Nose Throat Disorders | 1.7% | 0.6% | |
| Hormonal Disorders | 0.8% | 0.6% | |
| Mouth and Dental Disorders | 0.6% | 0.5% | |
| Non Malignant Disorders | 0.3% | 0.2% | |
| Nutritional Disorders | 0.3% | 0.2% | |
Central Nervous System was the leading therapy area for non-industry sponsored clinical trials in Q4 2022, accounting for a 27.7% share of all trials.
This was followed by the following therapy areas: Oncology with a 24.2% share, Cardiovascular with a 10.0% share, Infectious Disease with an 8.6% share, and Gastrointestinal with a 6.5% share.
In the last four quarters, Central Nervous System System held a lead over others for non-industry sponsored clinical trials with an average share of 26.1%, followed by Oncology with a 22.4% share, Infectious Disease with an 11.3% share, Cardiovascular with a 9.1% share, and Gastrointestinal with a 6.7% share.
| Non-Industry sponsored trials activity: 4-Quarter Avg. vs Q4 2022 | |||
|---|---|---|---|
| Therapy Area | 4-Quarter Avg. | Q4 2022 | Activity |
| Central Nervous System | 26.1% | 27.7% | |
| Oncology | 22.4% | 24.2% | |
| Cardiovascular | 9.1% | 10.0% | |
| Infectious Disease | 11.3% | 8.6% | |
| Gastrointestinal | 6.7% | 6.5% | |
| Metabolic Disorders | 5.8% | 5.5% | |
| Musculoskeletal Disorders | 5.3% | 5.3% | |
| Women’s Health | 4.8% | 4.9% | |
| Respiratory | 4.0% | 3.8% | |
| Genito Urinary System And Sex Hormones | 2.9% | 3.5% | |
| Dermatology | 3.1% | 3.4% | |
| Hematological Disorders | 2.9% | 3.3% | |
| Immunology | 2.9% | 3.2% | |
| Mouth and Dental Disorders | 2.9% | 2.5% | |
| Ophthalmology | 2.0% | 1.6% | |
| Ear Nose Throat Disorders | 1.0% | 1.2% | |
| Genetic Disorders | 0.7% | 1.1% | |
| Nutritional Disorders | 0.7% | 1.0% | |
| Hormonal Disorders | 0.8% | 0.8% | |
| Male Health | 0.7% | 0.5% | |
| Non Malignant Disorders | 0.4% | 0.3% | |
Top regions in industry and non-industry sponsored clinical trials activity in Q4 2022
Asia-Pacific held the top position for industry sponsored clinical trials activity in Q4 2022 with a 50.3% share, compared to 57.2% in the last four quarters.
North America stood at second place with a 36.8% share in Q4 2022, over 28.6% in the last four quarters, followed by Europe with a 27.6% share in Q4 2022, as against 25.6% in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held an 83.8% share in industry sponsored clinical trials in Q4 2022 when compared with 86.2% of average recorded in the last four quarters. Multinational trials accounted for a 16.2% share in Q4 2022, as against the four-quarter average of 13.8%.
Asia-Pacific region held the top position in non-industry sponsored clinical trial activity in Q4 2022 with a 57.2% share, over 54.5% in the last four quarters.
North America held the second position with a 19.3% share in Q4 2022, over 14.6% in the last four quarters, followed by Middle East and Africa with a 12.3% share in Q4 2022, as against 17.3% in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held a 98.9% share for non-industry sponsored clinical trials in Q4 2022, compared to 98.8% in the last four quarters. Multinational trials accounted for a 1.1% share in Q4 2022, as against 1.1% in the last four quarters.
Industry and non-industry sponsored clinical trials by Phase in Q4 2022
Phase II trials outnumbered all other studies with a 37.9% share for industry sponsored trials in Q4 2022, compared to 33.5% average in the last four quarters.
The share of Phase I trials stood at 35.0% in Q4 2022, as against the four-quarter average of 40.4%. Phase III trials held an 18.7% share in Q4 2022, registering an increase of 3.5% over the last four quarters average, followed by Phase IV trials with an 8.4% share in Q4 2022, as against the four-quarter average of 11.0%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Phase II trials outnumbered all other trials with a 49.0% share for non-industry sponsored clinical trials in Q4 2022, compared to 45.7% in the last four quarters.
Phase IV trials stood at second place with a 20.4% share in Q4 2022, compared to 21.1% in the last four quarters. Phase III trials held a 15.5% share in Q4 2022, as against 17.0% in the last four quarters, followed by Phase I trials with a 15.1% share in Q4 2022 over 16.2% average recorded in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
